UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 643,292 Shares of Omnicell, Inc. (NASDAQ:OMCL)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 86.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 97,334 shares of the company's stock after selling 643,292 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.21% of Omnicell worth $4,244,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. raised its holdings in shares of Omnicell by 61.3% in the second quarter. Assenagon Asset Management S.A. now owns 599,928 shares of the company's stock valued at $16,240,000 after buying an additional 228,093 shares during the last quarter. Federated Hermes Inc. grew its stake in shares of Omnicell by 1,113.6% during the 2nd quarter. Federated Hermes Inc. now owns 991,151 shares of the company's stock worth $26,830,000 after acquiring an additional 909,480 shares in the last quarter. Royce & Associates LP acquired a new stake in shares of Omnicell in the third quarter valued at about $811,000. Intech Investment Management LLC bought a new stake in Omnicell during the third quarter worth $753,000. Finally, Liontrust Investment Partners LLP acquired a new stake in shares of Omnicell in the second quarter valued at approximately $4,066,000. Institutional investors and hedge funds own 97.70% of the company's stock.

Omnicell Trading Up 0.1 %

Shares of OMCL stock traded up $0.05 during midday trading on Friday, reaching $46.01. 296,981 shares of the stock were exchanged, compared to its average volume of 535,995. The firm has a market cap of $2.13 billion, a PE ratio of -117.46, a price-to-earnings-growth ratio of 35.72 and a beta of 0.77. The company's 50 day moving average is $45.25 and its two-hundred day moving average is $38.90. Omnicell, Inc. has a 1 year low of $25.12 and a 1 year high of $55.74.

Insider Buying and Selling

In other news, Director Mark W. Parrish sold 12,000 shares of the stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total transaction of $567,600.00. Following the transaction, the director now directly owns 58,427 shares of the company's stock, valued at $2,763,597.10. This represents a 17.04 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 2.64% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

OMCL has been the subject of a number of recent research reports. Benchmark restated a "buy" rating and set a $48.00 price objective on shares of Omnicell in a research note on Wednesday, October 9th. Bank of America reaffirmed a "neutral" rating and set a $57.00 target price (up from $44.00) on shares of Omnicell in a research report on Thursday, October 31st. Barclays increased their price target on shares of Omnicell from $39.00 to $58.00 and gave the company an "equal weight" rating in a research report on Thursday, October 31st. Wells Fargo & Company lifted their price objective on shares of Omnicell from $30.00 to $41.00 and gave the stock an "equal weight" rating in a research report on Monday, October 14th. Finally, Craig Hallum raised their price target on shares of Omnicell from $45.00 to $64.00 and gave the stock a "buy" rating in a research note on Thursday, October 31st. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $52.00.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.